HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Clinical trial NCT05263453 · UNKNOWN
Trial details
- NCT number
- NCT05263453
- Sponsor
- Shanghai Kechow Pharma, Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-06
- Primary completion
- 2024-09-30
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.